JP Morgan Initiates Coverage On Adarx Pharmaceuticals with Overweight Rating, Announces Price Target of $38

JP Morgan analyst Tessa Romero has initiated coverage on Adarx Pharmaceuticals (NASDAQ: ADRX) with an Overweight rating. The firm has set a price target of $38 for the company's stock.